Renovo, plc.
Renovo, plc. (Template:Lse) is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research[1], and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe"[2] in 2009.
The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes[3].
Products
Currently the company doesn't have a marketed product, though its pipeline includes one drug that has recently initiated phase III clinical development, three drugs in phase II clinical development, and 13 other pre-clinical candidates.
| Drug | Phase | Action |
| Juvista | Phase III Clinical trial | scar prevention, also for vascular restenosis |
| Juvidex | Phase II Clinical trial | scar reduction, also for abdominal adhesions and eye scars |
| Prevascar | Phase II Clinical trial | scar prevention, also for nerves and eyes |
| Zesteem | Phase II Clinical trial | acute skin healing |